濮阳市东方医院技术很专业濮阳东方男科医院看病好吗,濮阳东方医院男科治疗早泄可靠吗,濮阳东方男科收费很低,濮阳东方医院男科看早泄评价很高,濮阳东方医院治疗阳痿很不错,濮阳东方医院男科治阳痿口碑好很放心,濮阳东方医院治早泄评价很好

BERLIN, Aug. 28 (Xinhua) -- Mercedes-Benz, the world leading luxury car producer, celebrates the 125th anniversary of its invention of automobile with what it claimed the largest gathering ever, at the former Tempelhof airport in Berlin on the weekend.The Mercedes-Benz Club and Mercedes-Benz enthusiasts greet visitors with some 1,800 well-assorted Mercedes-Benz-branded vehicles, ranging from vintage and classic passenger cars to a variety of historic commercial vehicles, on a vast open areas of 250,000 square metres of the abandoned Tempelhof airport, which was closed in 2008.It took Mr. Lauritzen and his wife two days' drive of their cherised wecker of Mercedes-Benz Cabriolet B. 320.W 142.-3,4l to reach here for taking part in the pageant."It is a long journey, but we are happy to be here to see more class cars and more friends with same interests," Mrs Lauritzen said.Owners take the opportunity to present their lovingly cared-for vehicles, which include a number of truly rare items of automotive history, to the Berlin public.The couple of Mr. Kerner drove their red Mercedes-Benz 170Dba, a made-in-1952 model with a range of special and unique designs which are very rarely seen now, over journey of 155 km from Bitterfeld to join in the gala."I'm fond of driving my classic car of Benz," said Mrs Kerner, despite it can run maximally at a speed of 50 to 80 km per hour, "but I truly enjoy the diesel engine sounds and the historic feeling it evokes."The legendary Silver Arrows, dating from the 1930s and 1950s, are also presented from the Mercedes-Benz Classic collection for demonstration drives."The brilliant history of the Silver Arrows will be brought to life with a demonstration of their impressive engine sound and incredible driving dynamics," said Michael Bock, head of Mercedes-Benz Classic and Director of Mercedes-Benz Museum GmbH."It is not often that these racing cars are driven in public, so this will be a true highlight of the program of events in Tempelhof."During the grand show, visitors are also accessible to first-hand experiences of the latest technologies applicable in the future for in passenger cars, commercial vehicles and racing cars."Some 125 years ago, Carl Benz submitted his patent application for the Benz Patent Motor Car to the Patent Office in Berlin", the organizer appealed to the visitors, saying now Mercedes-Benz is returning to Berlin to celebrate together with Berliners.

JIANGYIN, Jiangsu, July 1 (Xinhua) -- China's manned deep-diving submersible, the Jiaolong, embarked on a journey on Friday during which it will make a 5,000-meter dive in the Pacific Ocean.During the dive, the submersible will undergo several operational tests in which it will take photos, shoot video, survey seabeds and take samples from the ocean floor, according to Jin Jiancai, deputy director of the submersible's diving test program team.The tests will be conducted in the Pacific Ocean in accordance with a contract signed between the China Ocean Mineral Resources Research & Development Association and the International Seabed Authority (ISA).The submersible is scheduled to spend 47 days at sea, according to a statement from the Ministry of Science and Technology.A submersible differs from a submarine, as it typically depends on another vessel or facility for support.The Jiaolong, designed to reach a depth of 7,000 meters, completed 17 dives in the South China Sea between May 31 and July 18 last year, reaching 3,759 meters during its deepest dive.In the year since the submersible's last dive, program team members have made several technical improvements to the submersible and its support vessel, Jin said.Jin said the program team members are "very confident" about the test.He also stressed that the test will be carried out in accordance with the provisions of the United Nations Convention on the Law of the Sea as well as the ISA's rules and regulations.The Jiaolong is the world's first manned submersible designed to reach depths of 7,000 meters below sea level, according to Xu Qinan, the submersible's chief designer.

WASHINGTON, Aug. 2 (Xinhua) -- Breastfeeding protects against childhood obesity, but less than 4 percent of U.S. hospitals provide the full range of support mothers need for breastfeeding, according to a report issued by the Centers for Disease Control and Prevention Tuesday.Improving rates of breastfeeding by providing better hospital support to mothers and babies is an important strategy to improve children's health, including a reduced risk of childhood obesity, the monthly Vital Signs report said."Hospitals play a vital role in supporting a mother to be able to breastfeed," it said."Those first few hours and days that a mom and her baby spend learning to breastfeed are critical. Hospitals need to better support breastfeeding, as this is one of the most important things a mother can do for her newborn. Breastfeeding helps babies grow up healthy and reduces health care costs," it added.The report found only 14 percent of hospitals have a written and model breastfeeding policy.It also found in nearly 80 percent of hospitals, healthy breastfeeding infants are given formula when it is not medically necessary, a practice that makes it much harder for mothers and babies to learn how to breastfeed and continue breastfeeding at home.Additionally, only one-third of hospitals practise rooming in, which helps mothers and babies learn to breastfeed by allowing frequent chances to breastfeed.Finally, the report found in nearly 75 percent of hospitals, mothers and babies don't get the support they need when they leave hospitals, including a follow-up visit, a phone call from hospital staff and referrals to lactation consultants, and other important support systems in their communities.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

WASHINGTON, Sept. 12 (Xinhua) -- An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, U.S. researchers find.Over the course of four weeks, mice genetically engineered to lack the gene for protein kinase C (PKC) epsilon consumed less of a nicotine-containing water solution than normal mice, and were less likely to return to a chamber in which they had been given nicotine. In contrast, normal mice steadily increased their consumption of nicotine solution while the mice lacking PKC epsilon did not.The study conducted by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco, appeared Monday in the online edition of the Proceedings of the National Academy of Sciences.In normal mice, as in humans, nicotine binds to a certain class of nicotinic receptors located on dopamine neurons, which causes dopamine to be released in the brain. Dopamine creates a feeling of enjoyment, and thus prompts a sense of reward. Researchers found that mice lacking PKC epsilon are deficient in these nicotinic receptors.The finding complements earlier research in which researchers found that mice genetically engineered to lack the PKC epsilon enzyme drank less alcohol than normal mice and were disinclined to return to a chamber in which they had been given alcohol."This could mean that these mice might not get the same sense of reward from nicotine or alcohol," said Gallo senior associate director and investigator Robert Messing. "The enzyme looks like it regulates the part of the reward system that involves these nicotinic receptors."The reward system is a complex of areas in the brain that affect craving for nicotine, alcohol and other addictive substances.The next step in the research, said Messing, would be to develop compounds that inhibit PKC epsilon. The ultimate goal, he added, would be medications that could be used "to take the edge off of addiction by helping people get over some of their reward craving."